The NIHR Invention for Innovation (i4i) Programme is a translational research funding scheme aimed at medical devices, in vitro diagnostic devices and digital health technologies addressing an existing or emerging health or social care need.
They fund innovations that have demonstrated proof-of-concept and have a clear pathway towards adoption and commercialisation.
The i4i programme has three funding streams: Product Development Awards (PDA), Challenge Awards and Connect. i4i FAST (Funding At the Speed of Translation) is a funding scheme aimed at innovators in need of a small amount of funding to answer a specific question or to fund a single piece of activity.
The i4i programme is participating in the NIHR-wide themed call on reducing compound pressures, focusing on generating high-quality research evidence into the evaluation of health and care interventions and services to reduce compound pressures on the NHS and social care. And is working in collaboration with the Office for Life Sciences (OLS) on the Addiction Mission: Innovation for Treatment and Recovery (AMI) Awards.
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient…
From detecting TB, cancer, and heart attacks to diagnosing patients with strokes and diabetes, Artificial Intelligence (AI) is redefining the healthcare system across the world. Currently, more than 90% of hospitals and healthcare systems have implemented an AI or automation strategy,…